Pretreatment and prospective assessment of endometrium in menopausal women taking tamoxifen for breast cancer

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 132, Issue 1, 2007, Pages 101-106

  Garuti, Giancarlo ^a   Grossi, Francesco ^a   Centinaio, Giovanna ^a   Sita, Giulia ^a   Nalli, Giulio ^a   Luerti, Massimo ^a  

^a Lodi Hospital   (Italy)

Author keywords

Breast cancer; Endometrium; Hysteroscopy; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIAL DISEASE; ENDOMETRIUM; ENDOMETRIUM BIOPSY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; HYSTEROSCOPY; MAJOR CLINICAL STUDY; MENOPAUSE; MORBIDITY; NEUROLOGIC DISEASE; PREVALENCE; PRIORITY JOURNAL; SIDE EFFECT; THICKNESS; TRANSVAGINAL ECHOGRAPHY; VEIN THROMBOSIS;

EID: 34247367700     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejogrb.2006.04.001     Document Type: Article

References (24)

1. In: International Agency for Research on Cancer (IARC) (Ed). Tamoxifen. IARC monographs on the evaluation of carcinogenic risks to humans vol. 66 (1996), IARC, Lyon (France) 253-365
2. Lahti E., Blanco G., Kauppila A., Apaja-Sarkkinen M., Taskinen P.J., and Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 81 (1993) 660-664
3. Mignotte H., Lasset C., Bonadona V., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Int J Cancer 76 (1998) 325-330
4. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the national Surgical Adjuvant Breast and Bowel Project (NSABBP) B-14. J Natl Cancer Inst 86 (1994) 527-537
5. Cuzick J., Powels T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 (2003) 296-300
6. Berliere M., Charles A., Galant C., and Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol 91 (1998) 40-44
7. Gerber B., Krouse A., Muller H., et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 18 (2000) 3464-3470
8. Curtis R.E., Boice J.D., Shriner D.A., Hankey B.F., and Fraumeni J.F. Second cancers after adjuvant therapy for breast cancer. J Natl Cancer Inst 88 (1996) 332-334
9. Morrow M., Fine N.A., Singletary S.E., et al. Primary treatment of invasive breast cancer. In: Harris J.R., Lippman M.E., Morrow M., and Osborne C.K. (Eds). Disease of the breast. 2nd ed. (2000), Lippincott Williams and Wilkins, Philadelphia, PA, USA 515-645
10. Garuti G., Sambruni I., Colonnelli M., and Luerti M. Accuracy of hysteroscopy in predicting histopathology of endometrium in 1500 women. J Am Assoc Gynecol Laparosc 8 (2001) 207-213
11. Garuti G., Cellani F., Colonnelli M., Grossi F., and Luerti M. Outpatient hysteroscopic polypectomy in 237 patients: feasibility of a one-stop "see and treat" procedure. J Am Assoc Gynecol Laparosc 11 (2004) 500-504
12. Buckley C.H., and Fox H. Biopsy pathology of the endometrium. In: Gottlieb L.S., Neville A.M., and Walker F. (Eds). Biopsy Pathology Series 14 (1989), Chapman and Hall, London
13. Fleischer A.C., Wheeler J.E., Lindsay I., et al. An assessment of the value of ultrasonographic screening for endometrial disease in postmenopausal women without symptoms. Am J Obstet Gynecol 184 (2001) 70-74
14. Juneja M., Jose R., Kekre A.N., Viswanathan L., and Seshadri L. Tamoxifen-induced endometrial changes in postmenopausal women with breast carcinoma. Int J Gynecol Obstet 76 (2002) 279-284
15. Duffy S., Jackson T.L., Lansdown M., et al. The ATAC (Arimidex, Tamoxifen, alone or in combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 110 (2005) 1099-2006
16. Goncalves M.A.G., Goncalves N.J., Matias M.M., et al. Hysteroscopic evaluation of the endometrium of postmenopausal patients with breast cancer before and after tamoxifen use. Int J Gynecol Obstet 66 (1999) 273-279
17. Willen R., Lindahl B., Andolf E., Ingvar C., Liedman R., and Ranstam J. Histopathologic findings in thickened endometria, as measured by ultrasound in asymptomatic, postmenopausal breast cancer patients on various adjuvant treatment including tamoxifen. Anticancer Res 18 (1998) 667-676
18. Vosse M., Renard F., Coibion M., Neven P., Nogaret J.M., and Hertens D. Endometrial disorders in 406 breast cancer patients on tamoxifen: the case for less intensive monitoring. Eur J Obstet Gynecol Reprod Biol 101 (2002) 58-63
19. Neven P., De Muyider X., Van Belle Y., Van Hooff I., and Vanderlek G. Longitudinal hysteroscopic follow-up during tamoxifen treatment. Lancet 351 (1998) 36
20. Barakat R.R., Gilewski T.A., Almadrones L., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J Clin Oncol 18 (2000) 3459-3463
21. Seoud M., Shamseddine A., Khalil A., et al. Tamoxifen and endometrial pathology: a prospective study. Gynecol Oncol 75 (1999) 15-19
22. Fung M.F.K., Reid A., Faught W., et al. Prospective longitudinal study of ultrasound screening for endometrial abnormalities in women with breast cancer receiving tamoxifen. Gynecol Oncol 91 (2003) 154-159
23. Ceci O., Bettocchi S., Morello F., et al. Hysteroscopic evaluation of the endometrium in postmenopausal women taking tamoxifen. J Am Assoc Gynecol Laparosc 7 (2000) 185-189
24. Senkus-Konefka E., Konefka T., and Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treatment Rev 30 (2004) 291-301